Presenting 100% implant and prosthetic survival—10 years of clinical success with OsseoSpeed implants from Dentsply Sirona Implants

Dentsply Sirona Implants presents the latest data on the OsseoSpeed implants (Astra Tech Implant System): 100% implant and prosthetic survival rate after 10 years of clinical follow-up.

York/Salzburg, June 20, 2018. The prospective, investigator-initiates study* focused on the edentulous mandible, using immediate load and fixed prosthesis. The 10-year data reported exceptional long-term clinical results — 100% implant and prosthetic survival rate with minimal, 0.3 mm average bone level reduction — for immediately loaded OsseoSpeed implants.

“I am very proud, but not at all surprised, that we can present such solid long-term clinical results on the Astra Tech Implant System, as documented research is the foundation of the continuous development of our implant systems. In fact, we have solid, long-term clinical results on all our three implant systems. It really proves our commitment and dedication to science and clinical research,” says Anna-Karin Lundgren, DDS, PhD, Director Global Clinical Affairs at Dentsply Sirona Implants.

The implant systems — Astra Tech Implant System, Ankylos and Xive — are continuously documented and they are clinically proven to provide successful implant therapy for life-long function and esthetics.

Astra Tech Implant System
The extensive literature, approximately 1,000 publications, shows safe, consistent and predictable results for Astra Tech Implant System in terms of high implant survival rate and well maintained marginal bone. With more than 9,000 patients followed prospectively up to 20 years, the data shows implant survival rate above 98% and 0.3 mm average bone level reduction at the 5-year follow-up. Long-term clinical results up to 20 years are available.

Ankylos implant system
With up to 17 years of clinical reliability, a retrospective analysis** of 18,945 Ankylos implants placed in a large patient population (7,783 patients) showed successful long-term clinical results when using a flapless surgical approach. The Ankylos implant system has been in clinical use for more than 25 years and shows high survival rates and favorable esthetic results.

Xive implant system
With up to 15 years follow-up, data on Xive implants*** shows >97% survival rate, stable marginal bone levels, and favorable soft tissue conditions. The clinical documentation on 265 patients and 458 implants show excellent outcomes for single tooth, partial prosthesis, extraction sockets, immediate and delayed loading.

Press Release

Press Contact

Kerstin Wettby
Senior Manager
Global Marketing Communication & PR
Dentsply Sirona Implants
Aminogatan 1
SE-43121 Mölndal, Sweden
Phone: +46 705 16 32 02
kerstin.wettby@dentsplysirona.com

Sebastian Minas
MSL
Otto-Meßmer-Straße 1
D-60314 Frankfurt, Germany
Phone: +49 (0) 69 6612456-8349
sebastian.minas@mslgroup.com
www.mslgroup.de

About Dentsply Sirona Implants
Dentsply Sirona Implants offers comprehensive solutions for all phases of implant therapy, including Ankylos®, Astra Tech Implant System™ and Xive® implant lines, digital technologies, such as Atlantis™ patient-specific CAD/CAM solutions and Simplant® guided surgery, Symbios™ regenerative solutions, and professional and business development programs, such as STEPPS™. Dentsply Sirona Implants creates value for dental professionals and allows for predictable and lasting implant treatment outcomes, resulting in enhanced quality of life for patients.

About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 130-year history of innovation and service to the dental industry and patients in almost every country worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company™, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. Dentsply Sirona’s global headquarters is located in York, Pennsylvania, and the international headquarters is based in Salzburg, Austria. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Science and clinical research
Long-term clinical documentation is one of the most important tools to show a product’s efficiency, reliability and safety. Dentsply Sirona Implants focuses on research and development in all aspects of implant treatment, supported by extensive pre-clinical and clinical study programs. The comprehensive documentation includes more than 2,000 published scientific references to date and the products are researched, developed, documented and clinically proven to provide successful implant therapy for lifelong function and esthetics.

For more details about the Dentsply Sirona Implants clinical research program, please visit www.dentsplysirona.com/implants/science

References

IMAGES
are available for > Download on the website.